4D Molecular Therapeutics, Inc. (FDMT) financial statements (2022 and earlier)

Company profile

Business Address 5858 HORTON STREET #455
EMERYVILLE, CA 94608
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments247,777276,726
Cash and cash equivalents153,001276,726
Short-term investments94,776 
Receivables471,655
Other undisclosed current assets8,4564,275
Total current assets:256,280282,656
Noncurrent Assets
Operating lease, right-of-use asset14,562 
Property, plant and equipment14,3915,073
Long-term investments and receivables67,652 
Long-term investments67,652 
Other noncurrent assets602602
Total noncurrent assets:97,2075,675
TOTAL ASSETS:353,487288,331
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities12,5089,289
Accounts payable4,7641,787
Accrued liabilities7,7444,065
Employee-related liabilities 3,437
Deferred revenue2,5996,586
Other undisclosed current liabilities1,231869
Total current liabilities:16,33816,744
Noncurrent Liabilities
Long-term debt and lease obligation15,217 
Operating lease, liability15,217 
Liabilities, other than long-term debt2,82515,200
Deferred revenue2,49113,226
Other liabilities1201,852
Derivative instruments and hedges, liabilities214122
Total noncurrent liabilities:18,04215,200
Total liabilities:34,38031,944
Stockholders' equity
Stockholders' equity attributable to parent319,107256,387
Common stock33
Additional paid in capital526,523392,063
Accumulated other comprehensive loss(423) 
Accumulated deficit(206,996)(135,679)
Total stockholders' equity:319,107256,387
TOTAL LIABILITIES AND EQUITY:353,487288,331

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
Revenues18,03813,612
Gross profit:18,03813,612
Operating expenses(89,371)(70,276)
Operating loss:(71,333)(56,664)
Nonoperating income (expense)16(29)
Investment income, nonoperating137152
Other nonoperating expense(121)(181)
Net loss available to common stockholders, diluted:(71,317)(56,693)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
Net loss:(71,317)(56,693)
Comprehensive loss:(71,317)(56,693)
Other undisclosed comprehensive loss, net of tax, attributable to parent(423) 
Comprehensive loss, net of tax, attributable to parent:(71,740)(56,693)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: